Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: Implications for anti-idiotype vaccine development

Critical Reviews in Oncology/Hematology

Volumn 52, Issue 1, 2004, Pages 1-7

  Rodríguez Calvillo, Mercedes ^a   Inogés, Susana ^a   López Díaz De Cerio, Ascensión ^a   Zabalegui, Natalia ^a   Villanueva, Helena ^a   Bendandi, Maurizio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

B cell malignancies; bcl 2; Feasibility; Hybridoma; Idiotype vaccine; PCR; Recombinant technology

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; IMMUNOGLOBULIN;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RECURRENCE; CLINICAL TRIAL; DRUG SCREENING; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; HUMAN; HYBRIDOMA; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; REVIEW; VACCINATION; VACCINE PRODUCTION;

ANTIBODY FORMATION; CANCER VACCINES; EPITOPES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPES; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL;

EID: 4444274086     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.05.002     Document Type: Review

References (27)

1. Timmerman J.M. Immunotherapy for lymphomas. Int. J. Hematol. 77:2003;444-455
2. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev Anticancer Ther. 1:2001;65-72
3. Lynch R.G., Graff R.J., Sirisinha S., Simms E.S., Eisen H.N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA. 69:1972;1540-1544
4. Sugai S., Palmer D.W., Talal N., Witz I.P. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J. Exp. Med. 140:1974;1547-1558
5. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1992;1209-1215
6. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 89:1997;3129-3135
7. Bendandi M., Gocke C.D., Kobrin C.B., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5:1999;1171-1177
8. Barrios Y., Cabrera R., Yanez R., et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica. 87:2002;400-407
9. Nelson E.L., Li X., Hsu F.J., et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood. 88:1996;580-589
10. Spellerberg M.B., Zhu D., Thompsett A., King C.A., Hamblin T.J., Stevenson F.K. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 159:1997;1885-1892
11. Hawkins R.E., Russell S.J., Marcus R., et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027a. Hum Gene Ther. 8:1997;1287-1299
12. King C.A., Spellerberg M.B., Zhu D., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4:1998;1281-1286
13. Timmerman J.M., Singh G., Hermanson G., et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62:2002;5845-5852
14. McCarthy H., Ottensmeier C.H., Hamblin T., Stevenson F.K. Anti-idiotype vaccines. Br. J. Haematol. 123:2003;770-781
15. Timmerman J.M., Czerwinski D.K., van Beckhoven A. A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). Blood. 96:2000;578
16. Carroll W.L., Thielemans K., Dilley J., Levy R. Mouse × human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods. 89:1986;61-72
17. Bendandi M., Tonelli R., Maffei R., et al. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann. Oncol. 12:2001;1479-1484
18. Inoges S., Rodriguez-Calvillo M., Lopez-Diaz de Cerio A., et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica. 88:2003;1438-1440
19. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392
20. Wilson W.H., Neelapu S.S., Rosenwald A., et al. Idiotype vaccine and dose-adjusted EPOCH-Rituximab treatment in untreated mantle cell lymphoma: preliminary report on clinical outcome and analysis of immune response. Blood. 102:2003;358a
21. Gribben J.G., Freedman A., Woo S.D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 78:1991;3275-3280
22. Leonard J.P., Vose J., Timmerman J.M., et al. Recombinant idiotype-KLH vaccination (MyVax™) following CHOP chemotherapy in mantle cell lymphoma. Blood. 102:2003;357a
23. McCormick A.A., Kumagai M.H., Hanley K., et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. USA. 96:1999;703-708
24. Osterroth F., Garbe A., Fisch P., Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood. 95:2000;1342-1349
25. Zhu D., McCarthy H., Ottensmeier C.H., Johnson P., Hamblin T.J., Stevenson F.K. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 99:2002;2562-2568
26. Zhu D., Ottensmeier C.H., Du M.Q., McCarthy H., Stevenson F.K. Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. Br. J. Haematol. 120:2003;217-222
27. Zabalegui N., Lopes-Diaz de Cerio A., Inoqés S., et al. Acquized potential N-glycosylation within the tumor-specific immunoglobin heavy chains of B-cell malignancies. Haematologica. 89:2004;541-546